Premier Biomedical Statistics
Total Valuation
Premier Biomedical has a market cap or net worth of 988,991.
| Market Cap | 988,991 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Premier Biomedical has 1.10 billion shares outstanding.
| Shares Outstanding | 1.10B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +515.64% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.31 |
| PB Ratio | n/a |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.05
| Current Ratio | 0.05 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.46 |
| Interest Coverage | -0.83 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -153.58% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 3,570 |
| Profits Per Employee | -93,618 |
| Employee Count | 4 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 0.66 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +50.00% in the last 52 weeks. The beta is -4.77, so Premier Biomedical's price volatility has been lower than the market average.
| Beta (5Y) | -4.77 |
| 52-Week Price Change | +50.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 49.34 |
| Average Volume (20 Days) | 1,431,487 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.01 |
Income Statement
In the last 12 months, Premier Biomedical had revenue of 14,281 and -374,470 in losses. Loss per share was -0.01.
| Revenue | 14,281 |
| Gross Profit | 1,421 |
| Operating Income | -326,735 |
| Pretax Income | -374,470 |
| Net Income | -374,470 |
| EBITDA | -323,905 |
| EBIT | -326,735 |
| Loss Per Share | -0.01 |
Balance Sheet
The company has 71,197 in cash and 160,748 in debt, giving a net cash position of -89,551 or -0.00 per share.
| Cash & Cash Equivalents | 71,197 |
| Total Debt | 160,748 |
| Net Cash | -89,551 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | -1.83M |
| Book Value Per Share | -0.01 |
| Working Capital | -1.84M |
Cash Flow
In the last 12 months, operating cash flow was -344,180 and capital expenditures -4,850, giving a free cash flow of -349,030.
| Operating Cash Flow | -344,180 |
| Capital Expenditures | -4,850 |
| Free Cash Flow | -349,030 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 9.95% |
| Operating Margin | -2,287.90% |
| Pretax Margin | -2,622.16% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -2,444.02% |
Dividends & Yields
Premier Biomedical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,394.89% |
| Shareholder Yield | -1,394.89% |
| Earnings Yield | -793.89% |
| FCF Yield | -35.29% |
Stock Splits
The last stock split was on June 27, 2018. It was a reverse split with a ratio of 0.004.
| Last Split Date | Jun 27, 2018 |
| Split Type | Reverse |
| Split Ratio | 0.004 |
Scores
Premier Biomedical has an Altman Z-Score of -269.54. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -269.54 |
| Piotroski F-Score | n/a |